{"groups":[{"description":"Melphalan 100 mg/m\\^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily","id":"FG000","title":"No Bortezomib"},{"description":"Bortezomib (Level 1) 1.0 mg/m\\^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m\\^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily","id":"FG001","title":"Bortezomib 1.0 mg/m^2"},{"description":"Bortezomib (Level 2) 1.5 mg/m\\^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily","id":"FG002","title":"Bortezomib 1.5 mg/m^2"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Adverse Event"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"20"},{"groupId":"FG002","numSubjects":"20"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"20"},{"groupId":"FG002","numSubjects":"19"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Recruitment period June 2006 to December 2008. All participants recruited at UT MD Anderson Cancer Center."}